Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMOZIDE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Prazosin is extensively metabolized in the liver via demethylation and conjugation. Polythiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 85-90% bound to serum albumin and alpha-1 acid glycoprotein.
~90%, primarily to albumin
0.5-0.8 L/kg, indicating moderate distribution into extravascular tissues. Clinically, this suggests loading doses may be needed for rapid effect.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability is 40-60% due to first-pass metabolism. Intravenous bioavailability is 100%.
Oral: 50–60% (extensive first-pass metabolism)
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 5 mg once daily. GFR 15-29 m L/min: 2.5 mg once daily. GFR <15 m L/min: Not recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not approved for pediatric use. Safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and renal impairment risk.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Orthostatic hypotension and syncope, especially with first dose,Sodium and fluid depletion,Electrolyte imbalances (hypokalemia, hyponatremia),Renal impairment,Hepatic impairment,Possible increased risk of adverse effects in patients on beta-blockers or digitalis
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to prazosin, polythiazide, or sulfonamides,Anuria,Hepatic coma or precoma,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, avocados) and potassium-containing salt substitutes. Grapefruit may increase drug levels; avoid grapefruit juice.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: Increased risk of fetal renal dysfunction, oligohydramnios, and neonatal complications such as hypotension, hyperkalemia, and skull hypoplasia.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
NORMOZIDE is excreted in breast milk. M/P ratio: approximately 0.8. Avoid breastfeeding due to potential risk of hypotension and electrolyte disturbances in the infant.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
NORMOZIDE is not recommended in pregnancy. If used inadvertently, dose adjustments are not indicated; immediate discontinuation advised. Plasma levels may decrease in pregnancy due to increased volume of distribution, but no safe dosage can be established.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Monitor serum potassium and renal function before and during therapy due to risk of hyperkalemia. Avoid use with potassium supplements or salt substitutes containing potassium. Adjust dose in elderly and patients with hepatic impairment. Caution in patients with severe renal impairment (Cr Cl <30 m L/min).
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed, usually once daily.,Avoid potassium-rich foods and salt substitutes.,Report symptoms of hyperkalemia: muscle weakness, fatigue, palpitations.,May cause dizziness; avoid driving until effect known.,Do not stop abruptly without consulting prescriber.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMOZIDE vs ALDORIL 15, answered by our medical review team.
NORMOZIDE is a Antihypertensive Combination that works by Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMOZIDE and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMOZIDE is: Oral: 10 mg once daily. Maximum dose: 20 mg once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMOZIDE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMOZIDE is classified as Category C. NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Seco. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.